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Wild-type p53-induced phosphatase 1 (Wip1) is a newly identified serine/threonine 
phosphatase, which belongs to the PP2C family. Due to its involvement in stress- 
induced networks and overexpression in human tumors, primary studies have mainly 
focused on the role of Wip1 in tumorigenesis. It now has also been implicated in regu-
lating several other physiological processes such as organism aging and neurogenesis. 
Recent evidence highlights a new role of Wip1 in controlling immune response through 
regulating immune cell development and function, as well as through the interplay with 
inflammatory signaling pathways such NF-κB and p38 mitogen-activated protein kinase. 
In this short review, we will give an overview of Wip1 in immunity to better understand 
this important phosphatase.
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inTRODUCTiOn
Wild-type p53-induced phosphatase 1 (Wip1), which is a member of the PP2C (the type 2C family 
of protein phosphatases) family of phosphatases, is emerging as a direct p53 target in response to 
stresses (1). Based on the critical role of p53 in regulating tumor development, previous studies 
mainly focused on the role of Wip1 in controlling tumor transformation (2) and found that Wip1 
can regulate tumorigenesis through attenuating several stress-induced kinases activities (3). With 
newly emerging functions of Wip1 identified, more and more recent studies also suggested the 
critical role of Wip1 in a wide range of conditions such as aging (4) and adult neurogenesis (2). 
Since Wip1-deficient mice presented abnormal lymphoid tissue structure and increased suscepti-
bility to pathogens (5), the role of Wip1 in regulating immunity has also been investigated. In this 
review, we will give a brief introduction of Wip1 in regulating several signaling pathway networks 
in the context of immunity to deepen our knowledge on this important phosphatase.
An OveRview OF PHOSPHATASe wip1
Wip1 was discovered in 1997 by Fiscella and is a direct p53 target, which is rapidly induced by 
ionizing radiation in p53-positive cells (1). Primary studies focused on the role of Wip1 in DNA 
damage repair and suggested that Wip1 serves as a negative feedback regulator for DNA damage 
checkpoints (6–8). Several key molecules within the DNA-damage response network have been 
shown to be direct targets of Wip1 including p38 mitogen-activated protein kinase (MAPK) (7), 
ataxia-telangiectasia mutated (ATM) (8, 9), and cell cycle checkpoint kinase 2 (10). It is also sug-
gested that Wip1 is required for controlling H2A histone family in several cell lines after DNA 
damage in vitro (11–13). Since the function of DNA damage checkpoints is to preserve the genomic 
fidelity of proliferating cells and to prevent cellular transformation (6), the possible role of Wip1 
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in tumorigenesis is further studied. Wip1 deficiency can lead to 
the activation of p53, which plays a critical role in tumor sup-
pression and the enhanced ATM/p53-mediated apoptosis (14), 
thereby resulting in significantly attenuated tumorigenesis in 
two tumor models including c-myc-induced lymphoma (14, 15) 
and adenomatosis polyposis coli (Min) intestinal tumorigenesis 
(3). The deletion of Wip1 can also protect mice from mammary 
tumorigenesis in MMTV-Erbb2 and MMTV-HRAS1 mice in a 
p38 MAPK-dependent manner (16, 17). Moreover, other types 
of oncogenes such as products of Cdkn2a gene, p16lnk4a, and p19arf 
are also elevated in the absence of Wip1 and promote tumor 
suppression in mammary gland tumors. Consistent with these 
results, overexpression of Wip1 was reported in many human 
cancers (2). All these results further support the role of Wip1 
in regulating tumorigenesis. Interestingly, Wip1 overexpression 
in mice does not lead to spontaneous tumor appearance (18), 
and Wip1 overexpression in the mammary gland epithelium is 
also not sufficient to induce cancer (2, 19). Therefore, Wip1 may 
actually not act as a cancer-initiating oncogene on its own but 
provides advantages for tumor development through its func-
tion on multiple target molecules. Despite substantial evidence 
over the last decade that defines Wip1 as an onco-protein, recent 
studies have also shed lights on the role of Wip1 in regulating 
other normal and/or pathophysiological process due to its wide 
range of substrates, such as autophagy (20), aging (21), adult 
neurogenesis (4), and liver regeneration (22).
THe ROLe OF wip1 in iMMUniTY
wip1 in immune Cell Development 
and Function
Neutrophils
Our group has identified the critical role of Wip1 in mastering 
the development and function of neutrophils. The expression 
of Wip1 is gradually upregulated during the differentiation of 
myeloid precursors into mature neutrophils with the highest 
expression in resting mature neutrophils, and it can negatively 
regulate the generation and homeostasis of neutrophils in  vivo 
(23). Wip1-deficient mice displayed severe neutrophilia caused 
by the accelerated development of neutrophils in the bone 
marrow and higher CXCR2 (CXC chemokine receptor, CXCR) 
expression both on immature and mature neutrophils in the 
bone marrow. Higher expression of CXCR2 and lower expres-
sion of CXCR4 discovered in Wip1-deficient mice can drive 
the release of neutrophils from the bone marrow into the blood 
(23). Further mechanism studies showed that Wip1 negatively 
modulates the differentiation and maturation of neutrophils in 
a p38 MAPK-signal transducers and activators of transcription 
(STAT) 1-dependent manner (23). Moreover, the bactericidal 
activities and migration capacity of neutrophils are also tightly 
controlled by Wip1. The expression of Wip1 in human and 
mouse neutrophils was downregulated quickly after challenged 
by bacterial infection and pro-inflammatory cytokines (24). The 
downregulated expression of Wip1 was negatively related to the 
inflammatory cytokine production and bactericidal activities of 
neutrophils in a p38 MAPK-STAT1- and nuclear transcription 
factor (NF)-κB-dependent manner (24). Due to the importance 
of Wip1 in regulating neutrophil development and function, we 
also suggested that targets on Wip1 might be a new therapeutic 
strategy for the treatment of inflammatory bowel diseases (25) 
and intestinal ischemia reperfusion injury (26).
T Cells and Thymus
It was reported that young Wip1-deficient mice had smaller 
thymus, especially the thymic medulla. Analysis of thymocyte 
subset numbers showed that the number of TCRαβ [T cell 
receptor (TCR)]-positive thymocytes in Wip1-deficient mice 
was significantly decreased, while the number of TCRγδ-positive 
thymocytes remained normal (27). Detailed studies showed 
that there was no significant difference in the percentage of 
single positive (SP) thymocytes (CD4+ or CD8+) and double 
positive (DP) thymocytes (CD4+ CD8+) between wild-type 
and Wip1 knock out (KO) mice, but the number of these cells 
decreased. On the contrary, the number of thymocytes in the 
double negative (DN) stage (CD4− CD8−) is normal, while the 
ratio of DN thymocytes increased (27). These results indicated 
that thymocytes in Wip1-deficient mice displayed a defect in the 
process from DN stage to SP stage. Mechanism studies showed 
that the mRNA expression of Wip1 gradually increased during 
the process from DN3 (CD44− CD25+) stage to DN4 (CD44+ 
CD25−) stage, which resulted in the loss of inhibitory function 
of Wip1 on p53 protein activity. The upregulated activity of p53 
promoted cell cycle arrest with more cells in the S/G2/M phase, 
leading to a decrease in the number of cells in the DN4 stage, DP 
stage, and SP stage (27). The signaling pathway p38 MAPK was 
not involved in this process as p38 inhibitor could not rescue the 
thymic phenotype (27). Therefore, these results suggested that 
Wip1 is required for normal TCRαβ-positive T cell development 
through downregulating p53 activation in the thymus.
As previously described, Wip1-deficient mice had smaller 
thymus, especially the thymic medulla. Despite the impaired 
development of T cells in the thymus of Wip1-deficient mice, 
the role of Wip1 in regulating thymic epithelial cells (TEC) has 
also been studied. Based on the localization and distinctive cell 
surface markers, TEC are divided into two subsets, cortical TEC 
(cTEC) and medullary TEC (mTEC) (28), both of which arises 
from a common biopotent progenitor cell (29). Wip1 deficiency 
in thymic epithelium selectively leads to the decreased mTEC/
cTEC ratio, medullary thymic zone, and the percentage and 
total cell number of mTEC (30), all of which indicates a defect in 
mTEC differentiation. Further studies showed that Wip1 controls 
mTEC developmental kinetics during mTEC maturation but not 
the fetal stage through the p38 MAPK/CD40 pathway as Wip1 
deficiency does not affect the pool of thymic epithelia precursor 
cell, and the ratio of mature-to-immature mTEC is decreased in 
Wip1-deficient mice (30).
B Cells
The development of B cells is composed of several stages, 
pro-B cell, pre-B cell, and immature and mature B cell (31, 32). 
Wip1-deficient mice exhibit a remarkable reduction of B-cell 
numbers in the bone marrow, peripheral blood, and spleen (33). 
Through the establishment of mixed chimerism, studies showed 
FiGURe 1 | The involvement of wip1 in the development of immune cells.
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that the decreased number of B cells found in Wip1-deficient 
mice was mainly caused by the impaired development of B cells 
during the pre-B-cell stage as Wip1-deficient bone marrow 
cells (BMCs) differentiated into B cells in a lower efficiency 
compared with the WT BMCs and Wip1 deficiency also led 
to more cell death in pre-B cells (33). Since DNA recombina-
tion events induce DNA damage response which leads to p53 
activation and apoptosis during B-cell development (34, 35), 
the activation of p53 results in the upregulation of Wip1 which 
could dampen p53 protein level (33). Therefore, Wip1 serves as 
a negative feedback regulator to maintain the homeostatic level 
of p53 to support B-cell development, especially at the pre-B-
cell stage. Moreover, Wip1 is also suggested to play a critical role 
in preventing an aging-related decline in B-cell development as 
Wip1 deficiency exacerbates the impairment of the pre-B-cell 
development both in physiological aging and experimentally 
forced replicative aging (33).
Macrophages
Study on the role of Wip1 in regulating the development of mac-
rophages, as well as in the polarization of macrophages, is rare. 
However, in a recent study, Wip1 is suggested to play a critical role 
in regulating the conversion of macrophages into foam cells (20). 
In an apoE−/− mouse model of atherosclerosis, Wip1 deficiency 
resulted in a reduction in atherosclerotic plaque formation (20), 
which is mainly dependent on formation of foam cells (36). 
Consistent with these results, in vitro studies demonstrated that 
Wip1 deficiency led to a markedly reduced accumulation of 
foam cells from macrophages, as well as a significant reduction 
in the accumulation of cholesterylesters in macrophages (20). 
Further mechanism studies showed that deletion of Wip1 led 
to ATM-dependent activation of initiation and progression of 
autophagy in macrophages, which suppressed the conversion 
of macrophages into foam cell, thus preventing the development 
of atherosclerosis (20) (Figure 1).
FiGURe 2 | Schematic depicting signaling pathway networks of wip1 
and other relative proteins.
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wip1 in inFLAMMATiOn
Primary evidence for the involvement of Wip1 in inflammation 
comes from the study, which showed that Wip1-deficient mice 
presented abnormal lymphoid structure, with increased suscep-
tibility to ulcerated skin lesions and pathogens (5). We further 
demonstrated that Wip1 can modulate neutrophil function to 
regulate intestinal ischemia/reperfusion injury (26, 37) and 
inflammatory bowel diseases in a p38 MAPK-dependent manner 
(25). Moreover, Wip1 can also participate in neuro-inflammation 
through controlling tumor necrosis factor (TNF)-α synthesis (38) 
or NF-κB function (39). Further studies identified the interplay 
between Wip1 and NF-κB which plays an important role in 
cellular inflammatory response. NF-κB can activate WIP1 gene 
expression. The WIP1 gene has a conserved κB-binding site 
and the upregulation and inhibition of NF-κB function leads 
to increased and decreased Wipl expression, respectively. It was 
confirmed that the p65 subunit of NF-κB could directly bind to 
the upstream promoter of WIP1 gene to regulate its biological 
activity. On the other hand, Wipl can negatively regulate the 
expression of NF-κB. The inhibition of Wip1 can lead to the 
enhanced activation of NF-κB. The mRNA expression of NF-κB 
target molecules such as TNF-α in Wip1-deficient HeLa cells was 
increased, and the levels of NF-κB-dependent pro-inflammatory 
cytokines were also increased in Wip1-deficient splenic cells. 
Moreover, splenocytes in Wip1-deficient mice presented a pro-
inflammatory phenotype with increased ratio of cells expression 
CD80, MHC II, and CD40. On the contrary, HeLa cells with 
overexpression of Wip1 expressed much more decreased level 
of NF-κB-dependent cytokines. Detailed mechanism studies 
further showed that Wipl can inhibit the recruitment of NF-κB to 
co-transcription factor p300 by dephosphorylating P65 (Ser536) 
of NF-κB, leading to the inability of NF-κB to effectively activate 
the downstream pathway. In addition, Wipl can also inhibit the 
function of NF-κB by negative regulation of p38, resulting in 
reduced expression of NF-κB-dependent inflammatory factors 
such as IL-1, 6, and 8. Therefore, mechanism for Wip1 in regu-
lating inflammation can be described as follows: the activation 
of NF-κB by inflammatory signals can increase the expression 
of Wip1, which acts as a negative feedback regulator to inhibit 
NF-κB signaling and maintain the cell homeostasis through turn-
ing off the inflammatory process (Figure 2).
COnCLUDinG ReMARKS
Wip1 has long been recognized as an oncotarget, and therapeutic 
strategies to modulate its activity such as the use of Wip1 inhibi-
tor have also been suggested to be a promising treatment for 
patients with tumors. Despite the intrinsic interplay between 
Wip1 and other signaling pathways in tumor cells, substantial 
experimental evidence has identified the critical role of Wip1 
in regulating immunity through mastering immune cell devel-
opment and function through numerous signaling pathways 
including p38 MAPK, STAT1, NF-κB, and ATM/p53. Although 
there is no direct evidence for Wip1 in controlling immune 
system to promote tumor development, it is possible that Wip1 
can modulate tumor transformation through regulating immune 
system because of the tight relationship between inflammation 
and tumorigenesis.
Despite in regulating in immune system and tumorigenesis, 
Wip1 also displays a broader function in aging, liver regenera-
tion, and adult neurogenesis. All these facts raise the concern that 
although Wip1 can regulate numerous molecular networks, its 
function largely depends on cell type, the condition, and the age 
of organism. Moreover, due to its potent anti-inflammatory and 
anti-aging function, strategies to increase Wip1 expression to 
control inflammation and aging should also take into account 
possible pro-tumorigenic effect of Wip1 activation. Therefore, 
future studies on understanding the crosstalk between Wip1 
and multiple signaling pathways in different cells, as well as in 
whole organism level (i.e., immune system and secretion), may 
help to better develop potential therapeutic strategies based on 
phosphatase Wip1.
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